<DOC>
	<DOC>NCT01571206</DOC>
	<brief_summary>This open-label, single-arm, multicenter, multiple single-dose intravenous (IV) infusion, efficacy, and safety extension study of the Phase 1 Study CT-P13 1.1 is designed to assess the long-term efficacy and safety of multiple doses of CT-P13.</brief_summary>
	<brief_title>An Extension Study to Demonstrate the Equivalence of Long-Term Efficacy and Safety of CT-P13 in Patients With Ankylosing Spondylitis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 1.1</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patient who has completed the scheduled visits, including the EndofStudy Visit, in Study CTP13 1.1 Patient who has not had any major protocol violation in Study CTP13 1.1 Patient who has been withdrawn from Study CTP13 1.1 for any reason Patient who, at the time of providing informed consent, has any ongoing medical issues such as serious adverse events(SAEs) or intolerance issues that mean continuation in this extension study could be detrimental to their health, in the option of the investigator Patient who plans to participate in a study with an investigational drug during the period of this extension study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>AS</keyword>
	<keyword>Biosimilar</keyword>
</DOC>